{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:06:28Z","timestamp":1777633588191,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01400-8","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:21:16Z","timestamp":1772184076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Upfront Combination or Stepwise Escalation: Personalising LDL-C Reduction in Clinical Practice"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2948-6257","authenticated-orcid":false,"given":"Angela","family":"Pirillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"32","key":"1400_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144. A consensus statement from the European Atherosclerosis Society Consensus Panel.","journal-title":"Eur Heart J"},{"issue":"16","key":"1400_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jacc.2019.11.072","volume":"75","author":"D Preiss","year":"2020","unstructured":"Preiss D, Tobert JA, Hovingh GK, Reith C. Lipid-Modifying Agents, from Statins to PCSK9 inhibitors: JACC focus seminar. J Am Coll Cardiol. 2020;75(16):1945\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.072.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1400_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"42","key":"1400_CR4","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, van Roeters JE, et al. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359\u201378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","journal-title":"Eur Heart J"},{"key":"1400_CR5","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al: 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.. J Am Coll Cardiol. 2019;73(24):3168\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.002.","DOI":"10.1016\/j.jacc.2018.11.002"},{"issue":"10","key":"1400_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","volume":"21","author":"BA Ference","year":"2024","unstructured":"Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure hypothesis: evidence and practical applications. Nat Rev Cardiol. 2024;21(10):701\u201316. https:\/\/doi.org\/10.1038\/s41569-024-01039-5.","journal-title":"Nat Rev Cardiol"},{"issue":"44","key":"1400_CR7","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1093\/eurheartj\/ehaf567","volume":"46","author":"L Tokgozoglu","year":"2025","unstructured":"Tokgozoglu L, Barkas F, Ray KK, Gianos E. Great debate: fire-and-forget beats personalized lipid-lowering treatment. Eur Heart J. 2025;46(44):4751\u201361. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf567.","journal-title":"Eur Heart J"},{"issue":"6","key":"1400_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jacbts.2025.03.010","volume":"10","author":"E Ziogos","year":"2025","unstructured":"Ziogos E, Harb T, Valenta I, et al. Impact of In-Hospital PCSK9 Inhibition on myocardial inflammation after myocardial infarction: A randomized clinical trial. JACC Basic Transl Sci. 2025;10(6):709\u201320. https:\/\/doi.org\/10.1016\/j.jacbts.2025.03.010.","journal-title":"JACC Basic Transl Sci"},{"issue":"15","key":"1400_CR9","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae170","volume":"31","author":"P Gargiulo","year":"2024","unstructured":"Gargiulo P, Basile C, Galasso G, et al. Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry. Eur J Prev Cardiol. 2024;31(15):1806\u201316. https:\/\/doi.org\/10.1093\/eurjpc\/zwae170.","journal-title":"Eur J Prev Cardiol"},{"key":"1400_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/ehjacc\/zuaf137","author":"P Weltler","year":"2025","unstructured":"Weltler P, Harbich PF, Burger A, et al. The COR Lipid-Registry: the effectiveness of the strike early and strike strong strategy (SES) in patients with high cardiovascular risk. Eur Heart J Acute Cardiovasc Care. 2025. https:\/\/doi.org\/10.1093\/ehjacc\/zuaf137.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"2","key":"1400_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/ehjcvp\/pvaf004","volume":"11","author":"G Patti","year":"2025","unstructured":"Patti G, Cumitini L, Bosco M, et al. Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2025;11(2):143\u201354. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf004.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"1400_CR12","doi-asserted-by":"publisher","first-page":"e0286376","DOI":"10.1371\/journal.pone.0286376","volume":"18","author":"AK Ersboll","year":"2023","unstructured":"Ersboll AK, Kristensen MS, Nybo M, et al. Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: Danish cohort study. PLoS ONE. 2023;18(5):e0286376. https:\/\/doi.org\/10.1371\/journal.pone.0286376.","journal-title":"PLoS ONE"},{"issue":"5","key":"1400_CR13","doi-asserted-by":"publisher","first-page":"e069770","DOI":"10.1136\/bmjopen-2022-069770","volume":"13","author":"M Leosdottir","year":"2023","unstructured":"Leosdottir M, Hagstrom E, Hadziosmanovic N, et al. Temporal trends in cardiovascular risk factors, lifestyle and secondary preventive medication for patients with myocardial infarction attending cardiac rehabilitation in Sweden 2006\u20132019: a registry-based cohort study. BMJ Open. 2023;13(5):e069770. https:\/\/doi.org\/10.1136\/bmjopen-2022-069770.","journal-title":"BMJ Open"},{"issue":"15","key":"1400_CR14","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","volume":"85","author":"M Leosdottir","year":"2025","unstructured":"Leosdottir M, Schubert J, Brandts J, et al. Early Ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry. J Am Coll Cardiol. 2025;85(15):1550\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2025.02.007.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1400_CR15","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ehjacc\/zuac123","volume":"11","author":"KA Krychtiuk","year":"2022","unstructured":"Krychtiuk KA, Ahrens I, Drexel H, et al. Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the association for acute cardiovascular care (ACVC), in collaboration with the European association of preventive cardiology (EAPC) and the European society of cardiology working group on cardiovascular pharmacotherapy. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939\u201349. https:\/\/doi.org\/10.1093\/ehjacc\/zuac123.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"13","key":"1400_CR16","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711\u20138. https:\/\/doi.org\/10.1001\/jama.285.13.1711.","journal-title":"JAMA"},{"issue":"15","key":"1400_CR17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid Lowering with Statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504. https:\/\/doi.org\/10.1056\/NEJMoa040583.","journal-title":"N Engl J Med"},{"issue":"25","key":"1400_CR18","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to Statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"issue":"22","key":"1400_CR19","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"8","key":"1400_CR20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamacardio.2020.0882","volume":"5","author":"B Gencer","year":"2020","unstructured":"Gencer B, Mach F, Murphy SA, et al. Efficacy of Evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: A prespecified secondary analysis from the FOURIER trial. JAMA Cardiol. 2020;5(8):952\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2020.0882.","journal-title":"JAMA Cardiol"},{"key":"1400_CR21","doi-asserted-by":"publisher","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-3490a. https:\/\/doi.org\/10.1093\/eurheartj\/eht273","DOI":"10.1093\/eurheartj\/eht273"},{"issue":"2","key":"1400_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","volume":"223","author":"D Morrone","year":"2012","unstructured":"Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of Ezetimibe plus Statin and Statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251\u201361. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.02.016.","journal-title":"Atherosclerosis"},{"issue":"9965","key":"1400_CR23","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R, et al. PCSK9 Inhibition with Evolocumab (AMG 145) in heterozygous Familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(14)61399-4.","journal-title":"Lancet"},{"key":"1400_CR24","doi-asserted-by":"publisher","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G et al. ODYSSEY FH I and FH II: 78 week results with Alirocumab treatment in 735 patients with heterozygous Familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996\u20133003. https:\/\/doi.org\/10.1093\/eurheartj\/ehv370","DOI":"10.1093\/eurheartj\/ehv370"},{"issue":"16","key":"1400_CR25","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous Familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1913805.","journal-title":"N Engl J Med"},{"key":"1400_CR26","doi-asserted-by":"publisher","unstructured":"Vuorio A, Raal FJ, Kovanen PT. Elevated levels of lipoprotein(a) and low-density lipoprotein cholesterol in Familial hypercholesterolemia patients: is dual primary prevention already in sight? Front Cardiovasc Med. 2025;12(1624049). https:\/\/doi.org\/10.3389\/fcvm.2025.1624049.","DOI":"10.3389\/fcvm.2025.1624049"},{"issue":"12","key":"1400_CR27","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.mayocp.2025.01.018","volume":"100","author":"M Banach","year":"2025","unstructured":"Banach M, Jaiswal V, Ang SP, et al. Impact of Lipid-Lowering combination therapy with Statins and Ezetimibe vs Statin monotherapy on the reduction of cardiovascular outcomes: A Meta-analysis. Mayo Clin Proc. 2025;100(12):2152\u201371. https:\/\/doi.org\/10.1016\/j.mayocp.2025.01.018.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"1400_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","volume":"45","author":"MA Matter","year":"2024","unstructured":"Matter MA, Paneni F, Libby P, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur Heart J. 2024;45(2):89\u2013103. https:\/\/doi.org\/10.1093\/eurheartj\/ehad486.","journal-title":"Eur Heart J"},{"issue":"18","key":"1400_CR29","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L Raber","year":"2022","unstructured":"Raber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab added to High-Intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771\u201381. https:\/\/doi.org\/10.1001\/jama.2022.5218.","journal-title":"JAMA"},{"key":"1400_CR30","doi-asserted-by":"publisher","first-page":"120588","DOI":"10.1016\/j.atherosclerosis.2025.120588","volume":"412","author":"Y Ueki","year":"2025","unstructured":"Ueki Y, Kakizaki R, Otsuka T, et al. Effect of Alirocumab on coronary plaque stratified by atherothrombotic risk. Atherosclerosis. 2025;412:120588. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120588.","journal-title":"Atherosclerosis"},{"issue":"7","key":"1400_CR31","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of Evolocumab on coronary plaque phenotype and burden in Statin-Treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15(7):1308\u201321. https:\/\/doi.org\/10.1016\/j.jcmg.2022.03.002.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1400_CR32","doi-asserted-by":"publisher","unstructured":"Pradhan A, Sharma P, Prajapathi S, Aracri M, Iellamo F, Perrone MA. Intensive Lipid-Lowering therapy following acute coronary syndrome: the earlier the better. J Cardiovasc Dev Dis. 2025;12(8). https:\/\/doi.org\/10.3390\/jcdd12080300.","DOI":"10.3390\/jcdd12080300"},{"issue":"20","key":"1400_CR33","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","volume":"83","author":"MJ Koren","year":"2024","unstructured":"Koren MJ, Rodriguez F, East C, et al. An inclisiran first strategy vs usual care in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83(20):1939\u201352. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.382.","journal-title":"J Am Coll Cardiol"},{"key":"1400_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf685","author":"U Landmesser","year":"2025","unstructured":"Landmesser U, Laufs U, Schatz U, et al. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf685.","journal-title":"Eur Heart J"},{"issue":"6","key":"1400_CR35","doi-asserted-by":"publisher","first-page":"oeac071","DOI":"10.1093\/ehjopen\/oeac071","volume":"2","author":"M Banach","year":"2022","unstructured":"Banach M, Penson PE. Adherence to Statin therapy: it seems we know everything, yet we do nothing. Eur Heart J Open. 2022;2(6):oeac071. https:\/\/doi.org\/10.1093\/ehjopen\/oeac071.","journal-title":"Eur Heart J Open"},{"issue":"10085","key":"1400_CR36","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/S0140-6736(17)30754-7","volume":"389","author":"M Bohm","year":"2017","unstructured":"Bohm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389(10085):2226\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(17)30754-7.","journal-title":"Lancet"},{"key":"1400_CR37","doi-asserted-by":"publisher","unstructured":"Giugliano RP, Pedersen TR, Park JG et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)32290-0","DOI":"10.1016\/S0140-6736(17)32290-0"},{"issue":"7","key":"1400_CR38","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of Evolocumab. N Engl J Med. 2017;377(7):633\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1701131.","journal-title":"N Engl J Med"},{"issue":"5","key":"1400_CR39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","volume":"2","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Wiviott SD, Blazing MA, et al. Long-term safety and efficacy of achieving very low levels of low-Density lipoprotein cholesterol: A prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol. 2017;2(5):547\u201355. https:\/\/doi.org\/10.1001\/jamacardio.2017.0083.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"1400_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40292-025-00708-x","volume":"32","author":"SA Di Fusco","year":"2025","unstructured":"Di Fusco SA, Volpe M, Nardi F, et al. Reducing LDL-Cholesterol to very low levels: sailing between established benefits and potential risks. High Blood Press Cardiovasc Prev. 2025;32(2):139\u201349. https:\/\/doi.org\/10.1007\/s40292-025-00708-x.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"1400_CR41","doi-asserted-by":"publisher","unstructured":"Mansfield BS, Mohamed F, Larouche M, Raal FJ. The hurdle of access to emerging therapies and potential solutions in the management of dyslipidemias. J Clin Med. 2024;13(14). https:\/\/doi.org\/10.3390\/jcm13144160.","DOI":"10.3390\/jcm13144160"},{"issue":"1","key":"1400_CR42","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12916-020-01792-7","volume":"18","author":"PE Penson","year":"2020","unstructured":"Penson PE, Pirro M, Banach M. LDL-C: lower is better for longer-even at low risk. BMC Med. 2020;18(1):320. https:\/\/doi.org\/10.1186\/s12916-020-01792-7.","journal-title":"BMC Med"},{"issue":"4","key":"1400_CR43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40292-022-00529-2","volume":"29","author":"F Figorilli","year":"2022","unstructured":"Figorilli F, Mannarino MR, Bianconi V, Pirro M. Cholesterol-Lowering therapy in patients at Low-to-Moderate cardiovascular risk. High Blood Press Cardiovasc Prev. 2022;29(4):327\u201336. https:\/\/doi.org\/10.1007\/s40292-022-00529-2.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"1400_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf634","author":"T Tanaka","year":"2026","unstructured":"Tanaka T, Fukumoto Y. Lipid-lowering therapy for cardiovascular risk management in the older patients: how Far should we go? Eur J Prev Cardiol. 2026. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf634.","journal-title":"Eur J Prev Cardiol"},{"key":"1400_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf175","author":"RFE Pedretti","year":"2025","unstructured":"Pedretti RFE, Asteggiano R, Gevaert AB, et al. Cardiovascular risk factors management in older adults: a clinical consensus statement from the European association of preventive cardiology of the ESC and the ESC Council for cardiology practice. Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf175.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"1400_CR46","doi-asserted-by":"publisher","first-page":"e0264563","DOI":"10.1371\/journal.pone.0264563","volume":"17","author":"A Sasidharan","year":"2022","unstructured":"Sasidharan A, Bagepally BS, Kumar SS, Jagadeesh KV, Natarajan M. Cost-effectiveness of Ezetimibe plus Statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies. PLoS ONE. 2022;17(6):e0264563. https:\/\/doi.org\/10.1371\/journal.pone.0264563.","journal-title":"PLoS ONE"},{"key":"1400_CR47","doi-asserted-by":"publisher","unstructured":"Faggiano A, Gualeni A, Barbieri L, et al. Therapeutic inertia in dyslipidemia management for secondary cardiovascular prevention: results from the Italian ITACARE-P network. J Clin Med. 2025;14(2). https:\/\/doi.org\/10.3390\/jcm14020493.","DOI":"10.3390\/jcm14020493"},{"issue":"6","key":"1400_CR48","doi-asserted-by":"publisher","first-page":"500773","DOI":"10.1016\/j.arteri.2025.500773","volume":"37","author":"J Cosin Sales","year":"2025","unstructured":"Cosin Sales J, Escobar Cervantes C, Gomez-Barrado JJ, et al. Impact of therapeutic inertia in lipid-lowering therapy in patients at very high cardiovascular risk. Clin Investig Arterioscler. 2025;37(6):500773. https:\/\/doi.org\/10.1016\/j.arteri.2025.500773.","journal-title":"Clin Investig Arterioscler"},{"issue":"15","key":"1400_CR49","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/eurjpc\/zwae199","volume":"31","author":"KK Ray","year":"2024","unstructured":"Ray KK, Aguiar C, Arca M, et al. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol. 2024;31(15):1792\u2013803. https:\/\/doi.org\/10.1093\/eurjpc\/zwae199.","journal-title":"Eur J Prev Cardiol"},{"key":"1400_CR50","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100624.","journal-title":"Lancet Reg Health Eur"},{"key":"1400_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf399","author":"U Laufs","year":"2025","unstructured":"Laufs U, De Caterina R, Schiele F, et al. The ACS EuroPath survey series: time trends in lipid management after an acute coronary syndrome. Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf399.","journal-title":"Eur J Prev Cardiol"},{"issue":"38","key":"1400_CR52","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191.","journal-title":"Eur Heart J"},{"key":"1400_CR53","doi-asserted-by":"publisher","unstructured":"D\u2019Andrea D, Capone V, Bellis A, et al. PCSK9 inhibitors fast track use versus Stepwise Lipid-Lowering therapy in patients with acute coronary syndrome: A retrospective Single-Center study in a Real-World population. J Clin Med. 2025;14(9). https:\/\/doi.org\/10.3390\/jcm14092992.","DOI":"10.3390\/jcm14092992"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01400-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01400-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01400-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:21:17Z","timestamp":1772184077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01400-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1400"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01400-8","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AP has nothing to disclose. ALC has received honoraria, lecture fees, or research grants from Amarin, Amgen, Astrazeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceuticals, Medscape, Menarini, MSD, Novartis, NovoNordisk, Regeneron, Sanofi, Ultragenyx, and Viatris outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}